This is particularly apparent in the treatment of triple-negative breast cancer, which is negative for the expression of estrogen and progesterone receptors and HER2, and therefore not susceptible to hormone or HER2-targeted therapy. Here, ERBB2 is linked to triple-negative breast carcinoma.